CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 111 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age ≥18 years with metastatic RCC
  • ✓Candidate for first-line TKI treatment per investigator judgment and routine clinical practice
  • ✓No contraindications to TKI treatment
  • ✓ECOG performance status ≤2
Key exclusion· 8
  • ✕Not a candidate for first-line TKI treatment
  • ✕Prior systemic therapy (second-line or subsequent)
  • ✕Untreated hypothyroidism
  • ✕Untreated severe anemia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02789137
NCT02789137N/ACompleted
CompareCT.gov

PROSPECTIVE, MULTICENTRE, OBSERVATIONAL STUDY ON FATIGUE- AND HAND-FOOT SYNDROME-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING A TYROSINE KINASE INHIBITOR AS FIRST-LINE TREATMENT (TROYA STUDY).

Pfizer·observational·Posted Jun 2, 2016·Updated Nov 5, 2021

In Brief

An observational study for Metastatic Renal Cell Carcinoma. Completed, enrolled 111 participants across 23 sites.

Detailed Summary

The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome, with personal inter-variability, and to explore measures that can be taken in terms of both everyday lifestyle and treatment to mitigate or cure such side effects that affect patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesSpain
CollaboratorsTFS Trial Form Support

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2, 2016
Enrollment StartDec 22, 2016
Primary CompletionOct 20, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.1 years ago